This website is intended for healthcare professionals only

Conceptual design with brain and red abstract background. Horizontal banner.

Mechanical thrombectomy: Evidence basis and future directions

Abdelmageet Hassan, Sumanjit Gill

Both intracerebral hemorrhage and ischemic stroke continue to be the leading causes of disability and the second leading causes of death worldwide.1,2 The burden is largest in low- and middle-income countries, which have seen rapid recent population growth. Large vessel occlusion (LVO – internal carotids, vertebrals and the proximal branches of the circle of Willis) accounts for 20% of all acute ischemic strokes (AISs) […]

touchREVIEWS in Neurology. 2026;22(1):Online ahead of journal publication

Neuromuscular Diseases

FYI: New Therapeutic Strategies in Progressive Neuromuscular Disorders such as ALS

Published Online: Nov 21st 2012

An educational series from Duke Clinical Research Institute, presented by Richard Bedlack, MD, PhD, MS

Individualized myasthenia gravis treatment based on well-defined disease pathogenesis

Nils Erik Gilhus

Myasthenia gravis (MG) is an autoimmune disorder where antibodies disrupt the neuromuscular junction, causing muscle weakness that worsens with activity. MG subgroups are based on muscle weakness location, age, antibody type, and thymus pathology, with some patients experiencing severe, treatment-resistant symptoms. Biomarkers can indicate prognosis. First-line treatments include pyridostigmine for symptomatic relief and immunosuppressants like prednisolone and azathioprine. Thymectomy is recommended for certain patients. Second-line treatments include mycophenolate, rituximab, and others, with new therapies like complement and FcRn inhibitors showing promise. Intravenous immunoglobulin and plasma exchange are used for acute exacerbations. Supportive therapy, including adapted exercise, is crucial. In refractory cases, comorbidities and diagnosis accuracy should be reconsidered.

Related Videos in Neuromuscular Diseases

Developed by Touch

Anthony Béhin, EAN 2023: Highlights in myasthenia gravis

Dr Anthony Béhin (University Hospitals Pitié Salpêtrière, Paris, France) discusses highlights from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of myasthenia gravis. Disclosures: Anthony Béhin is a consultant for Alexion, Argenx, UCB, ...

Developed by Touch

Luca Leonardi, EAN 2023: Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis

Dr Luca Leonardi (Sapienza University of Rome, Italy) summarizes the take-home messages from his study assessing skin biopsy as a marker of disease onset and severity in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a treatable disease. The abstract ‘EJoN: Skin ...

Developed by Touch

Sabrina Sacconi, EAN 2023: The MycarinG study - rozanolixizumab in the treatment of muscle-specific kinase autoantibody-positive myasthenia gravis

Muscle-specific kinase autoantibody-positive (MuSK-Ab+) generalised myasthenia gravis (gMG) is usually more clinically severe than acetylcholine receptor autoantibody-positive (AChR-Ab+) gMG. The Phase 3 MycarinG study analysed rozanolixizumab in patients with AChR-Ab+ or MuSKAb+ gMG. Dr Sabrina Sacconi (Côte d’Azur University, ...

Developed by Touch

Sabrina Sacconi, EAN 2023: Highlights in myasthenia gravis

Dr Sabrina Sacconi (Côte d'Azur University, Nice, France) summarizes her top 3 highlights from the annual European Academy of Neurology (EAN), July 1–4, 2023 in the field of myasthenia gravis, an area with significant unmet needs for treatment options. It is an ...

Developed by Touch

Highlights from EAN 2023!

...

Developed by Touch

World Congress on Controversies in Neurology (CONy): Presidential highlights, Amos D. Korczyn

The 17th World Congress on Controversies in Neurology (CONy) took place March 23-25 2023 in Dubrovnik, Croatia. Prof. Amos D. Korczyn, CONy President (University of Tel-Aviv, Tel-Aviv, Israel) joined touchNEUROLOGY to discuss the main aims and focus of the recent CONy ...

Developed by Touch

Francesco Saccà, EAN 2022: Improving quality of life for patients with generalized myasthenia gravis - ADAPT trial findings

The ADAPT trial (NCT03669588) supported US Food and Drug Administration approval of efgartigimod alfa-fcab in generalized myasthenia gravis. Dr Francesco Saccà (University of Naples Federico II, Naples, Italy) discussed the findings of the study, in terms of health-related quality-of-life outcomes. ...

James Howard AAN 2022: Ravulizumab for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis – Results from the phase 3 CHAMPION-MG OLE trial

Ravulizumab has recently been approved by in the US for the treatment of adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). Prof. James Howard (The University of North Carolina at Chapel Hill, NC, USA) kindly joins touchNEUROLOGY ...

Developed by Touch

James Howard, AAN 2022: Unmet needs in the treatment of myasthenia gravis

Myasthenia gravis (MG) is a rare autoimmune disorder caused by antibodies that act against the myoneural junction, resulting in weakness of the skeletal muscles. Prof. James Howard (The University of North Carolina at Chapel Hill, CA, USA) discusses the unmet ...

Tuan Vu, AAN 2022: Ravulizumab for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis - Results from the phase 3 CHAMPION-MG trial

Ravulizumab has recently been approved by in the US for the treatment of adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). Prof. Tuan Vu kindly joins touchNEUROLOGY to discuss the phase 3 CHAMPION-MG trial that evaluated the efficacy ...

Developed by Touch

Michela Guglieri, AAN 2022: Safety and efficacy of corticosteroid regimens for Duchenne muscular dystrophy - Results of an international randomized controlled trial

Corticosteroids can improve muscle function in boys with Duchenne muscular dystrophy and are commonly prescribed for newly diagnosed patients. Dr Michela Guglieri (Newcastle University, Newcastle upon Tyne, United Kingdom) discusses a randomized, double-blind, parallel-group clinical trial investigating comparative safety and ...

Developed by Touch

Michela Guglieri, AAN 2022: Unmet needs and the role of corticosteroids in the treatment paradigm of Duchenne muscular dystrophy

Corticosteroids can improve muscle function in boys with Duchenne muscular dystrophy and are commonly prescribed for newly diagnosed patients. Dr Michela Guglieri (Newcastle University, Newcastle upon Tyne, United Kingdom) discusses the current unmet needs in DMD, and the role of ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Keep track of your clinical interests and newsletter subscriptions.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

Register now for FREE access

Already registered? Login below.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Learning Activities

Congress Highlights

Journals

Specialities

Mechanical thrombectomy: Evidence basis and future directions

Learning Activities

Congress Highlights

Journals

Specialities

Mechanical thrombectomy: Evidence basis and future directions

FYI: New Therapeutic Strategies in Progressive Neuromuscular Disorders such as ALS

Register now for
FREE access

Individualized myasthenia gravis treatment based on well-defined disease pathogenesis

Anthony Béhin, EAN 2023: Highlights in myasthenia gravis

Luca Leonardi, EAN 2023: Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis

Sabrina Sacconi, EAN 2023: The MycarinG study - rozanolixizumab in the treatment of muscle-specific kinase autoantibody-positive myasthenia gravis

Sabrina Sacconi, EAN 2023: Highlights in myasthenia gravis

Highlights from EAN 2023!

World Congress on Controversies in Neurology (CONy): Presidential highlights, Amos D. Korczyn

Francesco Saccà, EAN 2022: Improving quality of life for patients with generalized myasthenia gravis - ADAPT trial findings

James Howard AAN 2022: Ravulizumab for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis – Results from the phase 3 CHAMPION-MG OLE trial

James Howard, AAN 2022: Unmet needs in the treatment of myasthenia gravis

Tuan Vu, AAN 2022: Ravulizumab for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis - Results from the phase 3 CHAMPION-MG trial

Michela Guglieri, AAN 2022: Safety and efficacy of corticosteroid regimens for Duchenne muscular dystrophy - Results of an international randomized controlled trial

Michela Guglieri, AAN 2022: Unmet needs and the role of corticosteroids in the treatment paradigm of Duchenne muscular dystrophy

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Learning Activities

Congress Highlights

Journals

Specialities

Congress Highlights

Trending Topic

Connect With Us:

FYI: New Therapeutic Strategies in Progressive Neuromuscular Disorders such as ALS

Register now forFREE access

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

Register now for FREE access

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Register now for
FREE access